menu
    • menu
    [{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"REX-8756","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"REX-8756","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Recludix Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"BTK","graph1":"Immunology","graph2":"Discovery","graph3":"Recludix Pharma","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Recludix Pharma \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Recludix Pharma \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Recludix Pharma

    Menu

    Recludix Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $123.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Recludix Pharma Secures Funding for Novel SH2 Domain Inhibitors

                            Details : The collaboration aims to advance the development of an undisclosed miscellaneous product targeting BTK for chronic urticaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 12, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $123.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : REX-8756

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recludix Pharma Gets FDA Clearance for REX-8756 STAT6 Inhibitor Clinical Trial

                            Details : REX-8756, a miscellaneous product, targets STAT6 to address asthma, showcasing promising developments in the treatment of this condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2025

                            Lead Product(s) : REX-8756

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : REX-8756

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,325.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Recludix Names Oral STAT6 Inhibitor Candidate for Inflammatory Diseases with Sanofi

                            Details : The collaboration aims to advance preclinical studies, REX-8756, an oral, selective and reversible small molecule inhibitor of STAT6. It is being evaluated for asthma, COPD etc.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 02, 2025

                            Lead Product(s) : REX-8756

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,325.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Recludix Pharma

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,325.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Mul...

                            Details : Under the collaboration, Sanofi will have global rights to small molecule STAT6 inhibitors and Recludix will advance STAT6 inhibitors for patients with immunological and inflammatory diseases, from preclinical R&D until the start of Phase 2 clinical tria...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,325.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.